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Increasing tissue selectivity of compounds may aid the 
development of safer drug treatments by decreasing side 
effect prevalence. To enable this, improved insight into the 
mechanisms underlying tissue selectivity is required. In 
this article the influence of receptor concentration, drug-
target affinity and binding kinetics on tissue selectivity is 
described. Simulations were performed in a physiological 
model with drug-target binding, informed by in silico 
predicted physicochemical properties. Lower tissue 
selectivity was observed for high affinity ligands than for 
low affinity ligands. This observation moves against the 
current paradigm in which high affinity ligands are 
assumed to be better drug candidates. 
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INTRODUCTION 
The discovery of side effects in late-stage drug 
development or even after marketing is one of the leading 
causes of high drug attrition rates.1,2 This contributes to 
both increased financial risks and health risks.3 To reduce 
these risks side effects should be predicted in the earliest 
stages of drug development. This prediction requires a 
thorough understanding of the underlying mechanisms. 
 
An important cause of side effects is a lack of tissue 
selectivity (i.e. differential drug effect on the same receptor 
in different tissues). Tissue selectivity of adenosine A1-
receptor ligands in mice has been quantified by Van Schaik 
et al. and Van der Graaf et al.4,5 In these studies, the half-
maximal anti-lypolytic effect was observed at lower ligand 
concentrations than the half-maximal haemodynamic 
effect. The authors propose the receptor concentration as 
the determinant of the observed tissue selectivity. The 
relation between receptor concentration and drug effect is 
intuitive and commonly assumed. However, this 
assumption is a simplification of the underlying system, 
since many other factors may influence tissue selectivity. 
These factors include differential blood flow, tissue 
partitioning and tissue-specific ligand depletion rates. 
Since the interactions between these processes have not yet 
been fully investigated, our understanding of tissue 
selectivity is limited and additional research is required. 
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In addition to the influence of receptor concentration on 
tissue selectivity, the influence of binding kinetics should 
be taken into account to predict how tissue selectivity 
changes over time. The potential role of binding kinetics 
in drug selectivity is supported by the increased 
recognition of binding kinetics as an important mediator 
of drug effect.6–10 One of the main contributors to this 
recognition is the success of the residence time (RT) 
concept, which has been proven to be a better predictor of 
drug effect in vivo than drug-target affinity (KD). RT is 
dependent on a binding kinetic parameter: the dissociation 
constant (koff).  
 
To include binding kinetics into the prediction of 
selectivity, target mediated drug disposition (TMDD) 
models can be applied.11–14 The inclusion of target 
concentration in TMDD modelling makes it a useful tool 
for studying the influence of target concentration on drug-
target binding. Using physiological target concentration 
values enables the development of a predictive model. 
These values can be extracted from online databases. 
Tissue specific drug distribution properties can be 
described by tissue specific parameters. For this cause, 
physiologically based pharmacokinetic (PBPK) models 
have previously been developed.15 In PBPK models 
different compartments are assigned to specific 
organs/organ systems. Parameters such as blood flow and 
the tissue-blood partition (Pt:b) coefficient are used to 
define the physiological processes per tissue. Pt:b describes 
the amount of ligand that is distributed into a certain tissue 
and can be predicted from the physicochemical properties 
of the ligand. These physicochemical properties can be 
predicted in silico.16 Integrated TMDD and PBPK 
modelling forms a PBPK-TMDD model, which enables 
the simulation of drug-target binding in specific tissues. 
 
In this study we combine the available resources to predict 
drug and receptor concentrations in different tissues and 
the binding to their targets. We use these combined 
predictions to derive new insights about tissue selectivity 





All simulations were performed in RStudio Version 
0.99.893 - © 2009-2016 RStudio, Inc. Physicochemical 
parameters were predicted using Pipeline Pilot Version 
9.0.2.1 Accelrys Software Inc., San Diego (2014). 
 
Model 
A schematic overview of the applied model is depicted in 
Figure 1. The interactions between the descriptive 
parameters were described by differential equations. 
 
Figure 1. Schematic overview of the used PBPK-TMDD model. 
L = ligand concentration (nM), R = receptor concentration (nM), 
LR = ligand-receptor complex concentration (nM), kon = 
association constant (nM-1h-1), koff = dissociation constant (h-1), Q 
= blood flow (L/h), V = tissue volume (L), nbt = non-binding tissue, 
bt = binding tissue, li = liver, P = tissue-blood partition coefficient, 
kF: forward rate constant of elimination (h-1). 
 
Parameters 
Pt:b was set to 0.95 for all tissues in all simulations. Blood 
flow in binding tissues (Qbt1/2) was set to 20 L/h in all 
simulations. Binding tissue volume (Vbt1/2) was set to 1 L for 
receptor concentration (Rtot) simulations. For KD 
simulations, one set of simulations was performed with Vbt1/2 
set to 1 L and another with Vbt1/2 set to 20 L. kF was set to 
100 h-1. Dose was scaled so that similar receptor occupancies 
were obtained in all simulations. 
 
Simulations 
In order to investigate the influence of receptor 
concentration on tissue selectivity, simulations were 
performed using different values of Rtot for each of the two 
binding tissues. The simulations were performed for four 
different KD values. Rtot and KD values are specified in the 
figure legend and captions (Figure 2). 
 
To further investigate the influence of binding kinetics on 
tissue selectivity, simulations were performed for different 
KD values. These KD values were obtained via different 
combinations of association constant (kon) and koff. 
Simulations were performed for KD = 0.001, 0.01, 10, and 
1000 nM. koff values were set to 1, 0.1, 0.01, and 0.001 h-1 
for all simulations. kon values were then obtained by 
applying Equation 1. Values per simulation are displayed 
in the figure legends and captions (Figure 3 and 4). 
 





RESULTS AND DISCUSSION 
For high affinities (KD = 1*10-5 or 0.001 nM) combined with 
low koff rates (0.001 h-1) (Figure 2a and 2b), Rtot influences 
the extent, but not the duration of receptor occupancy (RO). 
This results in tissue selectivity for the tissue in which Rtot 
is the lowest. As drug-target affinity decreases, the RO 
values in the binding tissues grow more similar, until from 
KD = 1 onwards tissue selectivity is no longer observed 
(Figure 2a-c). When koff increases for low drug-target 
affinity (KD = 100), the duration of RO becomes more 
sensitive to differences in Rtot (Figure 2d). These results 
illustrate an important role for KD as well as Rtot in 
determining the extent of both RO and tissue selectivity. 
 
Figure 2. The influence of receptor concentration on receptor 
occupancy at different KD values. a: KD = 1*10-5 nM, kon = 100 
nM-1h-1, koff = 0.001 h-1, b: KD = 0.001 nM, kon = 1 nM-1h-1, koff = 
0.001 h-1, c: KD = 1 nM, kon = 0.001 nM-1h-1, koff = 0.001 h-1, d: KD 
= 100 nM, kon = 1 nM-1h-1, koff = 100 h-1. 
 
In order to further investigate the influence of binding 
kinetics on RO, simulations were performed for different KD 
values obtained via different combinations of kon and koff 
(Figure 3). In these simulations, selectivity was observed 
for the tissue with a low Rtot value (10 nM) when drug-
target affinity is high (KD = 0.001 or 0.01 nM) (Figure 3a 
and 3b). This selectivity decreases more rapidly for faster 
binding kinetics. However, the influence of binding kinetics 
decreases as drug-target affinity increases (Figure 3a). 
Selectivity for the tissue in which Rtot is the highest, even if 
only marginal, is observed when binding kinetics are fast 
and KD is equal to the highest Rtot (Figure 3c). 
 
The observations described above indicate that high drug-
target affinity does not guarantee high tissue selectivity for 
the target tissue. In fact, quite the opposite seems to be true. 
The desired effect of a ligand at the receptor is most 
commonly targeted at the tissue in which the Rtot is the 
highest. Therefore, the lower the RO in the tissue with the 
lower Rtot, the better. In this study, higher RO was observed 
in a tissue with an Rtot of 0.01 nM than in a tissue with an 
Rtot of 10 nM for the higher drug-target affinities (Figure 2 
and 3). This suggests selectivity for the off-target tissue 
rather than the target tissue. 
 
Figure 3. Increased receptor occupancy in tissues with lower 
receptor concentrations for ligands with a higher drug-target 
affinity as compared to ligands with a lower drug-target 
affinity. Q = 20 L/h, V = 20 L, kon is in nM-1h-1, koff is in h-1. a: KD 
= 0.001 (nM), b: KD = 0.01 nM, c: KD = 10 nM, d: KD = 1000 nM. 
 
The ratio of Qbt:Vbt was set to 1 in the simulations presented 
Figure 3. This value is lower than the values observed for 
most organs in the human body. Low Qbt:Vbt values limit the 
elimination of ligand from the tissue, prolonging the period 
during which drug-target binding may occur. This leads to 
an increase in the extent and duration of RO. When this 
occurs, Q is rate-limiting for the decline of RO over time. 
This effect may be observed for all values of Rtot, but is most 
pronounced for low Rtot values, since high values of Rtot 
limit the distribution of drug out of the tissue. 
 
In order to further clarify the influence of Qbt:Vbt on tissue 
selectivity, the same simulations as presented in Figure 3 
were performed for a Qbt:Vbt value of 20 (Figure 4). At this 
value, Qbt:Vbt is expected not to have a rate-limiting effect 
on RO. Roughly the same pattern of RO was observed as in 
Figure 3, but there are a couple of notable differences. As 
expected, an accelerated decline of RO over time was 
observed, mainly for the tissue with the lower target 
concentration. This accelerated decline of RO and drug-
target dissociation is most pronounced for faster binding 
kinetics (Figure 4a and 4b). This effect lasts until selectivity 
is reversed and is observed for the tissue with an Rtot of 10 
nM. 
  
Figure 4. Influence of binding kinetics and receptor 
concentration on tissue selectivity when blood flow-tissue 
volume ratio is 20. Q = 20 L/h, V = 1L = 20, kon is in nM-1h-1, koff 
is in h-1. a: KD = 0.001 (nM), b: KD = 0.01 nM, c: KD = 10 nM, d: 
KD = 1000 nM. 
 
The developed model was applied to the ligands studied by 
Van Schaick et al4, in order to validate the predictive 
potential of the developed model and the relevance of this 
research’s results. The required humane Rtot values were 
obtained from online expression databases, physiological 
parameters and KD were obtained from literature, high 
dissociation (koff = 10 h-1) was assumed, and the Pt:b values 
per humane tissue per ligand were predicted in silico.4,17–24 
The RO-based selectivity profile predicted by the developed 
model did not comply with the selectivity profile observed 
by Van Schaick et al.4 However, when predicting the 
absolute ligand-receptor binding based selectivity profile, 
the predicted profile does comply with the effect based 
selectivity as observed by Van Schaick et al. This implies an 
important role for absolute receptor binding on in vivo drug 
effect, confirms the predictive potential of our model and 
confirms the relevance of our observed results. 
 
Altogether, the results described in this article suggest that 
the quest for ligands with a high drug-target affinity at the 
receptor may not yield the safest and most efficacious 
therapeutic entities. In order to apply this new knowledge to 
the field of drug discovery, future research will be 
performed to quantify the influence of binding kinetics and 
physiological features on tissue selectivity. It will be 
attempted to create easy-to-use formulas to enable prediction 
of tissue selectivity. Furthermore, the model will be 
validated for a set of ligands of which binding kinetic data at 
the receptor is available, as well as tissue specific receptor 
concentrations and receptor occupancy measurements. 
Ultimately, the goal of future research is the development of 
an integrated model in which in silico predictions of binding 
kinetic are used to inform the PBPK-TMDD model in order 
to increase predictability of tissue selectivity.25 
 
CONCLUSION 
A combined effect of physiological properties and binding 
kinetics on tissue selectivity was observed. Most notable is 
the observation that high drug-target affinity may result in 
lower target tissue selectivity. Moving against the current 
paradigm in which high drug-target affinity is considered 
desirable, this research triggers the further investigation of 
the exact role of binding kinetics in tissue selectivity. 
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